Multi-Enzyme Supplementation After Mandibular Third Molar Surgery (Trypsin)
A Prospective Split-Mouth Evaluation of Multi-Enzyme Supplementation Following Mandibular Third Molar Surgery
This prospective, non-randomized, split-mouth pilot study evaluated the effects of multi-enzyme supplementation on postoperative recovery following bilateral impacted mandibular third molar surgery. Fifteen systemically healthy participants underwent two surgical procedures approximately one month apart. During the first session, the right mandibular third molar was extracted and standard postoperative care was provided. During the second session, the left mandibular third molar was extracted and the same standard care was supplemented with a seven-day course of bromelain, serratiopeptidase, trypsin, chymotrypsin, and nattokinase. Postoperative pain, facial edema, mouth opening, burning sensation, analgesic consumption, bleeding, and wound healing were evaluated during the first postoperative week. Each participant contributed both a control and an intervention surgical site.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This study was conducted as a prospective, non-randomized, split-mouth pilot investigation involving 15 systemically healthy participants aged 18-45 years with bilateral mesioangular impacted mandibular third molars classified as Pell and Gregory Class II, Position B. Each participant underwent two surgical sessions performed by the same surgeon approximately one month apart.
During the first session, the right mandibular third molar was extracted and participants received standard postoperative medication consisting of amoxicillin/clavulanic acid (875/125 mg) twice daily, paracetamol (500 mg) as needed, and a mouthwash containing 0.12% chlorhexidine gluconate and 0.15% benzydamine hydrochloride three times daily. During the second session, following clinical healing of the first surgical site, the left mandibular third molar was extracted. The same standard postoperative regimen was used, together with a dietary supplement containing bromelain (100 mg), serratiopeptidase (67 mg), trypsin (20 mg), chymotrypsin (10 mg), and nattokinase (60 FU), administered once daily for seven days.
All surgical procedures were performed under local anesthesia using articaine hydrochloride with epinephrine. A full-thickness mucoperiosteal flap was elevated, osteotomy was performed using a surgical chisel under sterile saline irrigation, and the surgical site was closed with 3/0 non-absorbable silk sutures.
Postoperative pain and burning sensation were assessed daily using a 0-10 scale. Analgesic consumption and the presence or absence of bleeding were recorded daily. Facial edema and mouth opening were evaluated through standardized clinical measurements. On postoperative day 7, wound healing was assessed using the Landry Wound Healing Index, ranging from 1 (very poor) to 5 (excellent). Each participant contributed one control and one intervention surgical site, allowing within-participant comparison of postoperative recovery.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Ankara, Turkey (Türkiye)
- Health Sciences University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Patients with bilateral impacted mandibular third molars classified as Class II, Position B according to the Pell and Gregory classification and mesioangular according to the Winter classification.
- Systemically healthy participants (ASA Class I).
- Participants aged 18-45 years.
- Willingness to participate and provision of informed consent.
Exclusion Criteria
- Age outside the specified range.
- Pregnancy or breastfeeding.
- Acute pericoronitis or signs of infection associated with the impacted third molar.
- Cystic or tumor-like lesions in the surgical region.
- History of allergies.
- Presence of systemic disease.
- Unwillingness to participate.
- Poor oral hygiene that may adversely affect wound healing.
- Tobacco or alcohol dependence.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Control Group
During the first surgical session, the right impacted mandibular third molar was extracted. Participants received standard postoperative care consisting of amoxicillin/clavulanic acid (875/125 mg) twice daily, paracetamol (500 mg) as needed, and a mouthwash containing 0.12% chlorhexidine gluconate and 0.15% benzydamine hydrochloride three times daily. No multi-enzyme supplement was administered. |
Pain will be assessed using a VAS on the 1st, 2nd, 3rd, and 7th postoperative days. For this purpose, the patient will be shown a 100-mm line with "0" at the left end and "100" at the right end. They will be instructed to mark the point on this line where their pain corresponds. The distance from the marked point to "0" will be measured with a ruler, and the resulting value will be recorded in mm to obtain the VAS score. Changes in these measurements will be recorded. In addition, the number of analgesics required by the patients up to the 7th postoperative day will be recorded. To assess edema, the tragus, lateral cauntus, corner of the mouth, and soft tissue pogonion points on the patient's face were marked preoperatively. Preoperatively, on the first, second, third, and seventh postoperative day, measurements will be taken and recorded between the Gonion-corner of the mouth, the Tragus-corner of the mouth, and the Gonion-lateral cauntus points. To assess trismus, the distance between the incisal edges of the upper and lower incisors will be measured and recorded with the mouth maximally open, preoperatively, and on the first, second, third, and seventh postoperative day. |
|
Experimental: Multi-Enzyme Supplementation Group
During the second surgical session, approximately one month after the first operation and following clinical healing, the left impacted mandibular third molar was extracted. Participants received the same standard postoperative care as in the control session, with the addition of a multi-enzyme dietary supplement containing bromelain (100 mg), serratiopeptidase (67 mg), trypsin (20 mg), chymotrypsin (10 mg), and nattokinase (60 FU), administered once daily for seven postoperative days. |
Pain will be assessed using a VAS on the 1st, 2nd, 3rd, and 7th postoperative days. For this purpose, the patient will be shown a 100-mm line with "0" at the left end and "100" at the right end. They will be instructed to mark the point on this line where their pain corresponds. The distance from the marked point to "0" will be measured with a ruler, and the resulting value will be recorded in mm to obtain the VAS score. Changes in these measurements will be recorded. In addition, the number of analgesics required by the patients up to the 7th postoperative day will be recorded. To assess edema, the tragus, lateral cauntus, corner of the mouth, and soft tissue pogonion points on the patient's face were marked preoperatively. Preoperatively, on the first, second, third, and seventh postoperative day, measurements will be taken and recorded between the Gonion-corner of the mouth, the Tragus-corner of the mouth, and the Gonion-lateral cauntus points. To assess trismus, the distance between the incisal edges of the upper and lower incisors will be measured and recorded with the mouth maximally open, preoperatively, and on the first, second, third, and seventh postoperative day. A dietary supplement containing bromelain (100 mg), serratiopeptidase (67 mg), trypsin (20 mg), chymotrypsin (10 mg), and nattokinase (60 FU), administered orally once daily for seven days after mandibular third molar surgery, in addition to standard postoperative care. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Wound healing
Time Frame: Postoperative day 7
|
Wound healing was assessed on postoperative day 7 using the Landry Wound Healing Index. The index ranges from 1 (very poor healing) to 5 (excellent healing), based on tissue color, bleeding on palpation, granulation tissue, incision margins, and suppuration. |
Postoperative day 7
|
|
Postoperative pain
Time Frame: Postoperative days 1-7
|
Postoperative pain intensity was recorded daily for seven days using a 0-10 visual analog scale, where 0 indicates no pain and 10 indicates the worst imaginable pain. Changes in pain scores over time were evaluated. |
Postoperative days 1-7
|
|
Postoperative Burning Sensation
Time Frame: Postoperative days 1-7
|
Burning sensation intensity was recorded daily for seven days using a 0-10 scale, where 0 indicates no burning sensation and 10 indicates the most severe imaginable burning sensation. |
Postoperative days 1-7
|
|
Facial Edema
Time Frame: Preoperative assessment and postoperative days 1, 2 and 7
|
Facial edema was assessed using standardized linear facial measurements between predefined anatomical landmarks. Measurements were obtained preoperatively and on postoperative days 1, 2 and 7. Changes in these measurements over time were evaluated. |
Preoperative assessment and postoperative days 1, 2 and 7
|
|
Mouth Opening (Trismus)
Time Frame: Preoperative assessment and postoperative days 1, 2 and 7
|
Maximum mouth opening was measured in millimeters as the interincisal distance between the upper and lower incisors. Changes in mouth opening were evaluated over the postoperative follow-up period. |
Preoperative assessment and postoperative days 1, 2 and 7
|
|
Postoperative Bleeding
Time Frame: Postoperative days 1-7
|
Participants recorded the presence or absence of postoperative bleeding daily for seven days. Bleeding was evaluated as a binary outcome (yes/no), and changes in bleeding probability over time were analyzed. |
Postoperative days 1-7
|
|
Postoperative Analgesic Consumption
Time Frame: Postoperative days 1-7
|
Participants recorded the number of analgesic tablets consumed daily during the first seven postoperative days. Daily analgesic consumption was compared between the control and intervention surgical sessions. |
Postoperative days 1-7
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of analgesic tablets consumed postoperatively
Time Frame: From postoperative day 1 to day 7
|
Participants will record the number of analgesic tablets taken each day for 7 days after surgery in a home diary. The total number of tablets consumed will be calculated. Unit of Measure: Number of tablets per patient |
From postoperative day 1 to day 7
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- 15.05.2025-2025/9-9/11
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Patient information will be kept confidential.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.